Data presentations will focus on the company's clinical and preclinical studies in IDH-mutated acute myeloid leukemia (AML) ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology ...

Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...

The presentations at ASH will cover the Phase 1a dose-escalation ... expressing optimism about ziftomenib's potential in the acute myeloid leukemia market. However, Stifel downgraded the ...

"The data being presented this year at ASH demonstrate Syndax's commitment ... patients with R/R mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML). Topline data is expected in the fourth ...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML ...

SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company, announced its participation in the upcoming American Society of Hematology (ASH) Annual Meeting, scheduled ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid ... at the 66th American Society of Hematology ...